Could Molnupiravir Be the First-Line Alternative Oral Antiviral Agent for COVID-19 Patients at High Risk?

J Korean Med Sci. 2024 Feb 19;39(6):e74. doi: 10.3346/jkms.2024.39.e74.
No abstract available

Publication types

  • Editorial

MeSH terms

  • Antiviral Agents / therapeutic use
  • COVID-19*
  • Cytidine / analogs & derivatives*
  • Humans
  • Hydroxylamines

Substances

  • molnupiravir
  • Hydroxylamines
  • Cytidine
  • Antiviral Agents